Literature DB >> 29230525

Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.

Yeun-Yoon Kim1, Chansik An1, Sungwon Kim1, Myeong-Jin Kim2.   

Abstract

OBJECTIVES: To evaluate the diagnostic performance of the LI-RADS (v2014) on gadoxetate-enhanced MRI prospectively applied in actual practice.
METHODS: We retrospectively reviewed the prospectively written radiology reports of 143 treatment-naïve at-risk patients who underwent gadoxetate-enhanced liver MRI from January to December 2014, and identified 202 hepatic observations categorized using the LI-RADS. The diagnostic performances of LI-RADS categories for hepatocellular carcinoma (HCC) and hepatic malignancy were calculated.
RESULTS: Twenty (69.0 %) of 29 LR-4, 73 (97.3 %) of 75 LR-5, and all of five (100 %) LR-5V observations were HCCs. The remaining two (2.7 %) LR-5 observations were combined hepatocellular-cholangiocarcinomas, while 10 (76.9 %) of 13 LR-M observations were HCCs. The sensitivity and specificity of LR-5/5V for HCC were 60.5 % and 97.3 %, respectively. Including LR-M in the diagnostic criteria for HCC increased sensitivity (68.2 %, p = 0.002) but decreased specificity without statistical significance (93.2 %, p = 0.154). LR-5/5V/M yielded sensitivity of 68.9 % and specificity of 100.0 % for hepatic malignancy.
CONCLUSIONS: LI-RADS v2014 was successfully applied on gadoxetate-enhanced MRI in clinical practice. LR-5/5V was the most specific diagnostic measure for HCC, but most LR-M observations were HCCs and a considerable portion of non-HCC malignancies were categorized as LR-4 or LR-5. KEY POINTS: • LR-5/5V provided a highly specific diagnosis for HCC. • Half of non-HCC malignancies were categorized as LR-4 or LR-5. • The majority of LR-M observations were finally diagnosed as HCCs. • More sensitive diagnosis of HCC was feasible with LR-5/5V/M on gadoxetate-enhanced MRI. • Observations in either LR-5/5V or LR-M categories were definitely malignant.

Entities:  

Keywords:  Diagnosis; Gadolinium DTPA disodium salt; Liver; Magnetic resonance imaging; Sensitivity and Specificity

Mesh:

Substances:

Year:  2017        PMID: 29230525     DOI: 10.1007/s00330-017-5188-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  17 in total

1.  Diagnostic criteria for hepatocellular carcinoma ⩽3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging.

Authors:  Sang Hyun Choi; Jae Ho Byun; Young-Suk Lim; Eunsil Yu; So Jung Lee; So Yeon Kim; Hyung Jin Won; Yong Moon Shin; Pyo Nyun Kim
Journal:  J Hepatol       Date:  2016-01-25       Impact factor: 25.083

Review 2.  Hepatobiliary agents and their role in LI-RADS.

Authors:  Thomas A Hope; Kathryn J Fowler; Claude B Sirlin; Eduardo A C Costa; Judy Yee; Benjamin M Yeh; Jay P Heiken
Journal:  Abdom Imaging       Date:  2015-03

3.  Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI.

Authors:  Ijin Joo; Jeong Min Lee; Sang Min Lee; Jeong Sub Lee; Jin Young Park; Joon Koo Han
Journal:  J Magn Reson Imaging       Date:  2016-04-18       Impact factor: 4.813

4.  Hepatocellular carcinoma likelihood on MRI exams: evaluation of a standardized categorization system.

Authors:  Nicholas Petruzzi; Donald Mitchell; Flavius Guglielmo; Patrick O'Kane; Sandeep Deshmukh; Christopher Roth; Conor Shortt; Stephen Balfour; Laurence Parker
Journal:  Acad Radiol       Date:  2013-03-28       Impact factor: 3.173

5.  Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI.

Authors:  Kathryn J Fowler; Arman Sheybani; Rex A Parker; Sean Doherty; Elizabeth M Brunt; William C Chapman; Christine O Menias
Journal:  AJR Am J Roentgenol       Date:  2013-08       Impact factor: 3.959

6.  Imaging Features of Biphenotypic Primary Liver Carcinoma (Hepatocholangiocarcinoma) and the Potential to Mimic Hepatocellular Carcinoma: LI-RADS Analysis of CT and MRI Features in 61 Cases.

Authors:  Theodora A Potretzke; Benjamin R Tan; Maria B Doyle; Elizabeth M Brunt; Jay P Heiken; Kathryn J Fowler
Journal:  AJR Am J Roentgenol       Date:  2016-02-11       Impact factor: 3.959

7.  Liver Imaging Reporting and Data System v2014 With Gadoxetate Disodium-Enhanced Magnetic Resonance Imaging: Validation of LI-RADS Category 4 and 5 Criteria.

Authors:  Sang Hyun Choi; Jae Ho Byun; So Yeon Kim; So Jung Lee; Hyung Jin Won; Yong Moon Shin; Pyo Nyun Kim
Journal:  Invest Radiol       Date:  2016-08       Impact factor: 6.016

8.  STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet; Herbert Y Kressel; Nader Rifai; Robert M Golub; Douglas G Altman; Lotty Hooft; Daniël A Korevaar; Jérémie F Cohen
Journal:  Radiology       Date:  2015-10-28       Impact factor: 11.105

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

Review 10.  Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology.

Authors: 
Journal:  Korean J Radiol       Date:  2017-04-03       Impact factor: 3.500

View more
  22 in total

1.  Longitudinal evolution of CT and MRI LI-RADS v2014 category 1, 2, 3, and 4 observations.

Authors:  Cheng William Hong; Charlie C Park; Adrija Mamidipalli; Jonathan C Hooker; Soudabeh Fazeli Dehkordy; Saya Igarashi; Mohanad Alhumayed; Yuko Kono; Rohit Loomba; Tanya Wolfson; Anthony Gamst; Paul Murphy; Claude B Sirlin
Journal:  Eur Radiol       Date:  2019-02-26       Impact factor: 5.315

2.  The inhibitory effect of gadoxetate disodium on hepatic transporters: a study using indocyanine green.

Authors:  Hiroyuki Akai; Koichiro Yasaka; Akira Kunimatsu; Masanori Nojima; Yusuke Inoue; Osamu Abe; Kuni Ohtomo; Shigeru Kiryu
Journal:  Eur Radiol       Date:  2018-04-12       Impact factor: 5.315

3.  Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?

Authors:  Ijin Joo; Jeong Min Lee; Dong Ho Lee; Ju Hyeon Jeon; Joon Koo Han
Journal:  Eur Radiol       Date:  2018-09-25       Impact factor: 5.315

4.  Comparison between M-score and LR-M in the reporting system of contrast-enhanced ultrasound LI-RADS.

Authors:  Li-Da Chen; Si-Min Ruan; Yuan Lin; Jin-Yu Liang; Shun-Li Shen; Hang-Tong Hu; Yang Huang; Wei Li; Zhu Wang; Xiao-Yan Xie; Ming-De Lu; Ming Kuang; Wei Wang
Journal:  Eur Radiol       Date:  2018-12-19       Impact factor: 5.315

Review 5.  Pitfalls and problems to be solved in the diagnostic CT/MRI Liver Imaging Reporting and Data System (LI-RADS).

Authors:  Yeun-Yoon Kim; Jin-Young Choi; Claude B Sirlin; Chansik An; Myeong-Jin Kim
Journal:  Eur Radiol       Date:  2018-08-16       Impact factor: 5.315

6.  How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?

Authors:  Hong Seon Lee; Myeong-Jin Kim; Chansik An
Journal:  Eur Radiol       Date:  2018-12-14       Impact factor: 5.315

7.  Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.

Authors:  Xianlun Zou; Yan Luo; John N Morelli; Xuemei Hu; Yaqi Shen; Daoyu Hu
Journal:  Abdom Radiol (NY)       Date:  2021-03-03

Review 8.  Problematic lesions in cirrhotic liver mimicking hepatocellular carcinoma.

Authors:  Myeong-Jin Kim; Sunyoung Lee; Chansik An
Journal:  Eur Radiol       Date:  2019-02-20       Impact factor: 5.315

Review 9.  Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients.

Authors:  Victoria Chernyak; Kathryn J Fowler; Aya Kamaya; Ania Z Kielar; Khaled M Elsayes; Mustafa R Bashir; Yuko Kono; Richard K Do; Donald G Mitchell; Amit G Singal; An Tang; Claude B Sirlin
Journal:  Radiology       Date:  2018-09-25       Impact factor: 11.105

10.  Validation of the Liver Imaging Reporting and Data System Treatment Response Criteria After Thermal Ablation for Hepatocellular Carcinoma.

Authors:  Katherine S Cools; Andrew M Moon; Lauren M B Burke; Katrina A McGinty; Paula D Strassle; David A Gerber
Journal:  Liver Transpl       Date:  2019-12-20       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.